{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T12:10:48Z","timestamp":1775823048171,"version":"3.50.1"},"reference-count":32,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Urologia"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Prostate cancer is the most common solid neoplasm in men, with an increasing incidence. This study describes clinical and sociodemographic features and PSA levels, and evaluate their associations with stage, risk categories, metastasis, and mortality in a public tertiary hospital in southern Colombia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology:<\/jats:title>\n                    <jats:p>\n                      The present retrospective cohort study included 590 patients diagnosed with prostate cancer between 2020 and 2023. Sociodemographic and clinical variables, PSA levels, pathological characteristics and risk scales were analyzed. Patients were categorized into two groups: living (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009429) and deceased by prostate cancer (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009109), and other causes (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200944). Statistical analyses were performed to determine associations with mortality and presence of metastasis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      PSA screening was more frequent among survivors (66.9%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009287) than among deceased (22.0%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200924;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Median PSA at diagnosis was higher in those who died (123 vs 16\u2009ng\/mL;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001). PSA\u2009&gt;\u2009100\u2009ng\/mL was associated with ~50% probability of metastatic disease, rising to &gt;95% for PSA\u2009&gt;\u2009323\u2009ng\/mL. High-risk D\u2019Amico classification was strongly associated with metastasis (RR 6.67) and mortality (OR 14.24,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Bone pain was the predominant presenting symptom in the deceased group (76.1%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200983) and showed a strong association with metastasis (RR 8.146).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>PSA screening was strongly associated with improved survival outcomes. Elevated PSA levels, high risk D\u2019Amico classification and the presence of bone pain were important predictors of metastasis and mortality. The need to strengthen early detection in our population is evident, given the high percentage of patients presenting at advanced stages.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03915603251412607","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:01:35Z","timestamp":1768284095000},"page":"212-220","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["No screening, no life: Perspectives from a sociodemographic characterization of prostate cancer patients"],"prefix":"10.1177","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1271-2860","authenticated-orcid":false,"given":"Lucas J.","family":"Cort\u00e9s","sequence":"first","affiliation":[{"name":"Facultad de Ciencias de la Salud, Universidad Surcolombiana. Hospital Universitario Hernando Moncaleano Perdomo, Neiva, Huila, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8837-9665","authenticated-orcid":false,"given":"Germ\u00e1n","family":"Olaya","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Universitaria Ciencias de la Salud (FUCS), Bogot\u00e1 D.C, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0723-020X","authenticated-orcid":false,"given":"Jos\u00e9 S.","family":"Cort\u00e9s","sequence":"additional","affiliation":[{"name":"Universidad Nacional de Colombia, Bogot\u00e1 D.C, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan I.","family":"Caicedo","sequence":"additional","affiliation":[{"name":"Hospital Universitario Fundaci\u00f3n Santa Fe de Bogot\u00e1, Bogot\u00e1 D.C, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge A.","family":"Fl\u00f3rez","sequence":"additional","affiliation":[{"name":"Hospital Universitario Hernando Moncaleano Perdomo. Universidad Surcolombiana, Neiva, Huila, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"Leslie SW Soon-Sutton TS. Prostate cancer. StatPearls Publishing 2024. https:\/\/www.ncbi.nlm.Nih.gov\/books\/NBK470550\/ (accessed 17 March 2024)."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncoscience.527"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.14905"},{"key":"e_1_3_3_5_2","unstructured":"Ferlay J Ervik M Lam F et al. International agency for research on cancer. Glob Cancer Obs https:\/\/gco.iarc.who.int\/today\/en (2024)."},{"key":"e_1_3_3_6_2","unstructured":"Cuenta de Alto Costo C. D\u00eda mundial del c\u00e1ncer de pr\u00f3stata 2025. https:\/\/cuentadealtocosto.org\/noticias\/dia-mundial-del-cancer-de-prostata\/ (2025)."},{"key":"e_1_3_3_7_2","unstructured":"PDQ Screening and Prevention Editorial Board. Prostate Cancer Prevention (PDQ\u00ae): Patient Version. PDQ Cancer Inf Summ. https:\/\/www.cancer.gov\/types\/prostate\/patient\/prostate-prevention-pdq (2002 accessed 17 March 2024)."},{"key":"e_1_3_3_8_2","unstructured":"Oliveros C Almanza M Vasquez K et al. Caracterizaci\u00f3n cl\u00ednica y sociodemogr\u00e1fica de los pacientes con c\u00e1ncer de pr\u00f3stata que consultaron en el Hospital Universitario Erasmo Meoz en el periodo 2018-1 a 2021-1. Rev Sinerg - Hosp Univ Erasmo Meoz. https:\/\/herasmomeoz.gov.co\/wp-content\/uploads\/2022\/02\/ARTICULO-11.pdf (2022)."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-20117-4"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2022.100360"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/1073274820915720"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2021.02.002"},{"key":"e_1_3_3_13_2","first-page":"641","article-title":"The role of alternative medicine and complimentary therapies in urologic disease: New horizons","volume":"91","author":"Bizzarri FP","year":"2024","unstructured":"Bizzarri FP, Campetella M, Ragonese M, et al. The role of alternative medicine and complimentary therapies in urologic disease: New horizons. Urol J 2024; 91: 641\u2013646.","journal-title":"Urol J"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.03.016"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13411"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2024.10.005"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-6051.24.05792-6"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34671"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2015.16.13.5137"},{"key":"e_1_3_3_20_2","article-title":"Systematic review of clinical features of suspected prostate cancer in primary care","volume":"61","author":"Young SM","year":"2015","unstructured":"Young SM, Bansal P, Vella ET, et al. Systematic review of clinical features of suspected prostate cancer in primary care. Can Fam Physician 2015; 61: e26\u2013e35.","journal-title":"Can Fam Physician"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.315739.118"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2016.09.019"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.19966"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2008.150508"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.08.059"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.07.082"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.12954\/PI.14054"},{"key":"e_1_3_3_28_2","unstructured":"David MK Leslie S. Prostate specific antigen. StatPearls. https:\/\/pubmed.ncbi.nlm.nih.gov\/32491427\/ (2024 accessed 17 March 2024)."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.06.014"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.11.002"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002289"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.245605"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04995-5"}],"container-title":["Urologia Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603251412607","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03915603251412607","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603251412607","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T11:35:11Z","timestamp":1775820911000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03915603251412607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1177\/03915603251412607"],"URL":"https:\/\/doi.org\/10.1177\/03915603251412607","relation":{},"ISSN":["0391-5603","1724-6075"],"issn-type":[{"value":"0391-5603","type":"print"},{"value":"1724-6075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]}}}